PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 28, 2026Therapeutic Advances in Rare Disease0 citationsOpen Access

Miglustat Enhances Cipaglucosidase Alfa Stability in Late-Onset Pompe Disease

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease

View Full Paper
Ask AI
Bookmark
Share

Authors

HDHolly DubbsBBBarry J. ByrneSASampath Arepalli

Discussion

Loading...

Member takes

Overview

Clinical data reveals improved treatment outcomes in late-onset Pompe disease with miglustat and cipaglucosidase alfa, suggesting enhanced therapy efficacy.

Key Points

  • The study aims to evaluate the efficacy and safety of miglustat in combination with cipaglucosidase alfa for late-onset Pompe disease.
  • Utilized preclinical studies in Pompe mouse models
  • Conducted clinical trials to assess safety and efficacy in patients with Pompe disease
  • Examined functional outcomes and biomarker levels in patients using the combination therapy
  • Cipaglucosidase alfa exposure improved with miglustat co-administration
  • Enhanced uptake into target tissues was observed
  • Functional outcomes showed significant improvement compared to cipaglucosidase alfa alone
  • Miglustat was well tolerated with fewer gastrointestinal events when dosed bi-weekly

Cite This Study

Dubbs et al. (2026) studied this question.

synapsesocial.com/papers/69a287570a974eb0d3c0306bhttps://doi.org/10.1177/26330040261425686
View Full Paper
Ask AI
Bookmark
Share